Nabriva Therapeutics plc Banner Image

Nabriva Therapeutics plc has reached its limit for free report views

Work for Nabriva Therapeutics plc? Upgrade Your Profile and unlock all your annual reports.

Nabriva Therapeutics plc

  • Ticker NBRV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Nabriva Therapeutics plc Logo Image
  • 51-200 Employees
  • Based in Dublin, Ireland
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, they submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the UnitedMore States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Their corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.
Nabriva Therapeutics plc

Most Recent Annual Report

Nabriva Therapeutics plc
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Nabriva Therapeutics plc has reached its limit for free report views.

Older/Archived Annual Reports